Menopause: Finding the Right Clinical Trial

What Is Menopause and Why Does It Generate So Much Research?

Menopause is a single point in time: the last menstrual period, confirmed after 12 consecutive months without bleeding. The broader transition, called perimenopause, can begin 4 to 8 years earlier and involves erratic estrogen fluctuation, irregular cycles, and early vasomotor symptoms. The 2023 Menopause Society position statement defines this biology in detail and underpins most active trial designs.

The Scale of the Problem

Roughly 1.3 million American women reach menopause every year. Up to 80% experience hot flashes, and approximately 27% rate them as severe enough to disrupt sleep, work, or daily activity, according to data from the Study of Women's Health Across the Nation (SWAN) cohort published in JAMA Internal Medicine. Bone loss accelerates by 1 to 3% per year in the first 5 years after the final period. Urogenital atrophy affects roughly 50% of postmenopausal women yet is reported to a clinician by fewer than 25%.

Why Trials Are Still Needed

Despite decades of research, three knowledge gaps keep study enrollment active:

• Long-term cardiovascular safety of newer progestogen formulations such as micronized progesterone versus medroxyprogesterone acetate
• Efficacy of neurokinin B (NKB) antagonists beyond 52 weeks
• Comparative effectiveness of low-dose vaginal estrogen versus ospemifene for genitourinary syndrome of menopause (GSM)

Each gap represents an open trial somewhere in the pipeline, and that trial may match your symptom profile exactly.

How Menopause Clinical Trials Are Structured

Phase Definitions You Need to Know

Clinical trials follow a four-phase framework. Phase 1 studies focus on safety in small groups (20 to 80 participants). Phase 2 explores dosing and preliminary efficacy, typically in 100 to 300 women. Phase 3 confirms efficacy and monitors adverse events in larger populations, usually 500 to 3,000 participants. Phase 4 trials run after regulatory approval and track long-term outcomes in real-world populations.

Most women searching for a menopause trial will qualify for Phase 2, Phase 3, or Phase 4 studies, since Phase 1 trials in this therapeutic area frequently require healthy women without significant comorbidities and set narrow hormonal assay thresholds.

Trial Designs Common in Menopause Research

Randomized controlled trials (RCTs) remain the gold standard. The Women's Health Initiative (WHI), which enrolled 161,808 women aged 50 to 79, is the best-known example. A 2017 reanalysis published in JAMA found that women aged 50 to 59 who received conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) had a 12% lower all-cause mortality over 18 years of follow-up compared to placebo, a finding that reframed the risk-benefit conversation for younger perimenopausal women.

Crossover designs appear in GSM and sexual function trials because the endpoint is patient-reported, and washout periods allow each participant to serve as her own control. Observational registry studies, such as those using the SWAN database, generate hypothesis-level evidence that later gets tested in RCTs.

Primary Endpoints You Will See on Consent Forms

• Vasomotor symptoms (VMS): Mean daily moderate-to-severe hot flash frequency, typically measured over 12 weeks against baseline
• Bone mineral density (BMD): Dual-energy X-ray absorptiometry (DXA) change at lumbar spine and femoral neck
• Vulvovaginal atrophy (VVA) / GSM: Vaginal pH, superficial cell percentage on maturation index, and patient-reported pain with intercourse
• Quality of life: Menopause-specific tools such as the Menopause-Specific Quality of Life (MENQOL) questionnaire or Greene Climacteric Scale

The Landmark Trials That Set the Evidence Baseline

Understanding the trials already completed helps you recognize what a new study is building on or correcting.

Women's Health Initiative (WHI)

Launched in 1991, the WHI remains the largest menopause RCT ever conducted. The CEE-plus-MPA arm was stopped early in 2002 after a mean of 5.6 years because of a statistically significant increase in invasive breast cancer (HR 1.26, 95% CI 1.00 to 1.59). The CEE-alone arm (for women with prior hysterectomy) continued to 7.1 years and showed no increased breast cancer risk and a possible reduction in breast cancer incidence (HR 0.77, P<0.001 in the updated 2020 analysis). Full data appear in the NIH WHI program publications.

KEEPS and ELITE Trials

The Kronos Early Estrogen Prevention Study (KEEPS, N=727) and the Early vs Late Intervention Trial with Estradiol (ELITE, N=643) both tested the "timing hypothesis": that MHT started close to menopause may reduce cardiovascular risk, whereas starting late does not. ELITE, published in NEJM in 2016, showed that oral 17-beta estradiol started within 6 years of menopause significantly slowed carotid intima-media thickness progression compared to placebo, while initiation more than 10 years after menopause showed no such benefit.

SKYLIGHT 1 and SKYLIGHT 2 (Fezolinetant)

These Phase 3 trials (combined N>1,000) evaluated fezolinetant 30 mg and 45 mg versus placebo over 12 weeks, with a 40-week extension. At 12 weeks, fezolinetant 45 mg reduced moderate-to-severe VMS frequency by approximately 60% from baseline versus 45% for placebo. The FDA approved fezolinetant (Veozah) in May 2023 based on this data, as documented on the FDA drug approval page. This was the first approval in a new class of non-hormonal agents targeting the neurokinin 3 receptor.

How to Find the Right Menopause Trial for You

Step 1: Define Your Primary Symptom Domain

Trials are built around specific endpoints. Enrolling in a GSM trial when your chief complaint is severe hot flashes means you may receive an intervention that does not address your worst symptom. Before searching, assign yourself to one of these four domains:

1. Vasomotor symptoms (hot flashes, night sweats)
2. Genitourinary syndrome of menopause (vaginal dryness, dyspareunia, recurrent UTIs)
3. Bone health (early postmenopause osteopenia, fracture prevention)
4. Mood, cognition, and sleep disruption

Step 2: Search ClinicalTrials.gov With Precision Filters

Go to ClinicalTrials.gov and use these filters together:

• Condition: "Menopause" or "Vasomotor Symptoms" or "Genitourinary Syndrome of Menopause"
• Status: "Recruiting" or "Not yet recruiting"
• Age: your current age
• Location: your city or a radius in miles

Add the intervention term if you want a specific drug class. Typing "neurokinin" returns NKB antagonist trials; typing "ospemifene" or "vaginal estradiol" narrows to GSM studies. Each result shows the NCT number, sponsor, phase, estimated enrollment, primary endpoint, and key inclusion/exclusion criteria.

Step 3: Read Inclusion and Exclusion Criteria Carefully

The criteria below appear on the majority of Phase 2 and Phase 3 VMS trials. Think of them as a five-filter checklist before you contact any site.

| Criterion | Typical Requirement | |---|---| | Menopause status | FSH >40 IU/L plus 12 months amenorrhea, or surgical menopause | | Hot flash frequency | ≥7 moderate-to-severe VMS per day at screening | | Hormone washout | No systemic MHT for 8-12 weeks; no vaginal estrogen for 4 weeks | | BMI range | Usually 18-38 kg/m² | | Liver function | Normal ALT/AST (relevant for fezolinetant-class drugs given hepatotoxicity signal) | | Breast/uterine cancer history | Most hormonal trials exclude personal history; some non-hormonal trials do not |

If you do not meet even one major criterion, the site coordinator will screen you out at the first phone call. Confirming fit before that call saves time for both sides.

Step 4: Contact the Site Coordinator, Not the Principal Investigator

Site coordinators run day-to-day enrollment. They know the real-world screening timeline, whether the trial still has open slots, and whether a planned interim analysis might pause enrollment. The principal investigator (PI) is typically available only after you pass the screening visit. Asking to speak with the PI before the screening call is a common mistake that delays the process.

Step 5: Understand What Participation Requires

A typical Phase 3 VMS trial asks for:

• A 2-week run-in period with a daily symptom diary (electronic or paper)
• Screening bloodwork and possibly a pelvic ultrasound (for trials using estrogen)
• 4 to 8 clinic visits over 12 to 52 weeks, plus possible phone or telehealth check-ins
• A final off-drug follow-up visit

Transportation costs are often reimbursed. Study drug, labs, and clinic visits are covered by the sponsor. No copay or insurance billing occurs for protocol-mandated procedures.

Matching Your Symptom Profile to Specific Trial Categories

Vasomotor Symptom Trials

The most active enrollment area in 2024 and 2025 targets NKB pathway antagonists as follow-ons to fezolinetant, SERM combinations, and new transdermal estradiol micro-dose patches. Women with moderate-to-severe hot flashes who have a contraindication to estrogen (personal history of estrogen-receptor-positive breast cancer, active thromboembolism, or uncontrolled hypertension) are particularly valuable to non-hormonal VMS trial sponsors because this population was historically excluded from all MHT key trials.

The Menopause Society 2023 position statement explicitly states: "For women with bothersome VMS who are not candidates for hormone therapy, newer non-hormonal options including fezolinetant and oxybutynin provide clinically meaningful relief." Trials testing these agents at expanded doses or in special populations continue to recruit.

GSM and Sexual Function Trials

Ospemifene (Osphena), a selective estrogen receptor modulator (SERM) approved for dyspareunia in 2013, was studied in the AURORA trial series, which showed a 36% reduction in the most bothersome symptom score versus placebo at 12 weeks. Active Phase 4 and registry studies now track ospemifene's long-term endometrial safety and compare it to low-dose vaginal estradiol in a head-to-head format. Women who are breast cancer survivors represent a specific subgroup enrolling in non-estrogenic GSM trials, since even vaginal estrogen remains controversial in that population per the NAMS 2022 GSM position statement.

Bone Health and Fracture Prevention Trials

The USPSTF recommends screening for osteoporosis with bone density testing in all women aged 65 and older and in younger postmenopausal women whose 10-year fracture risk equals or exceeds that of a 65-year-old white woman, as outlined in their 2018 recommendation statement. Women with osteopenia (T-score between -1.0 and -2.5) represent the target for fracture prevention trials testing antiresorptive agents, bisphosphonates at new doses, or investigational anabolic peptides alongside estrogen.

MHT's bone benefit is well-established. The Cochrane review by Marjoribanks et al. (last updated 2017, N=41 trials) confirmed that MHT reduces vertebral and non-vertebral fracture risk, with fracture reduction maintained for up to 5 years after stopping therapy. Combination trials now ask whether adding an anabolic agent to MHT offers superior BMD gains compared to either agent alone.

Cognitive and Mood-Related Trials

Sleep disruption and mood changes, including anxiety and depressive symptoms, affect approximately 40% of perimenopausal women according to the SWAN data published in Archives of General Psychiatry. Phase 2 trials in this domain test whether treating VMS with MHT or NKB antagonists secondarily improves polysomnographic sleep architecture, or whether sleep improvements are independent of VMS reduction. Women with a prior major depressive episode who enter perimenopause are a distinct enrollment target because their biological vulnerability to mood relapse during hormonal fluctuation is disproportionately high.

Navigating Eligibility Barriers and Common Pitfalls

The Hormone Washout Problem

The most common reason women are screened out of VMS trials is active hormone use. A 3-month systemic MHT washout and a 4-week vaginal estrogen washout are standard. During the washout, your symptoms may worsen. Some protocols offer a non-randomized bridging option: a short course of a fully approved symptomatic agent such as paroxetine 7.5 mg (Brisdelle) during washout, followed by a second screening visit. Ask the site coordinator whether this option exists before agreeing to a washout period.

BMI Thresholds and Why They Matter

Many trials set an upper BMI limit around 38 to 40 kg/m². Higher BMI creates circulating estrone from peripheral aromatization of androgens, which can both raise baseline FSH variability and reduce the signal-to-noise ratio on VMS frequency endpoints. If you are above the BMI cutoff, search for trials that specifically enroll women with obesity, or look at metabolic-menopause intersection trials that are designed for this population from the outset.

Prior Cancer History

A personal history of estrogen-receptor-positive (ER-positive) breast cancer excludes enrollment in nearly all MHT trials. It does not automatically exclude enrollment in non-hormonal trials using NKB antagonists, SERMs that have demonstrated breast tissue neutrality, or device-based interventions such as stellate ganglion block studies. The key is to search by intervention class, not just by condition name, on ClinicalTrials.gov.

Reading the Informed Consent Document

Every federally regulated clinical trial must provide an informed consent document (ICD) that discloses known and theoretical risks, the right to withdraw at any time without penalty, who to call in a medical emergency, and whether the study involves a placebo arm. For hormone-containing trials, the ICD will specifically reference the WHI findings and contextualize them relative to your age and health status.

The FDA's guidance on informed consent for clinical investigations outlines the minimum required elements. Reading the ICD with your personal physician before signing is good practice. Bring a list of all current medications, including supplements, because many trials exclude St. John's wort, high-dose soy isoflavones, or CYP3A4 inhibitors that could interfere with study drug pharmacokinetics.

What Happens to Your Data After the Trial Ends

De-identification and Archiving

All U.S. Clinical trial data collected under an FDA Investigational New Drug (IND) application are de-identified and archived. The sponsor retains the right to use anonymized data in regulatory submissions. Your individual records remain in the clinical site's system under your study ID, not your name, and are stored for a minimum of 15 years per 21 CFR Part 312.

Access to Results

Sponsors are legally required to post summary results on ClinicalTrials.gov within 12 months of the primary completion date under the Final Rule issued in 2016. You can search your trial's NCT number to find these results, including adverse event tables, after the trial closes. If the trial leads to a publication, you will not be named but the study population will be described, and you may recognize your enrollment cohort by the demographics listed.

Open-Label Extension Studies

Phase 3 menopause trials sometimes offer an open-label extension (OLE) to participants who completed the blinded period. In an OLE, all participants receive the active drug at the dose that performed best in the blinded phase. Fezolinetant's 40-week OLE data, presented at the 2022 Menopause Society annual meeting, showed that VMS frequency reductions were maintained through week 52 with no new safety signals beyond those identified at 12 weeks. Enrolling in the OLE is voluntary, and you may decline without affecting your access to standard care.

A Practical Timeline From First Search to First Dose

Most women spend 4 to 8 weeks between their first ClinicalTrials.gov search and receiving their first dose. The typical path:

1. Week 1: Search ClinicalTrials.gov, identify 2 to 4 candidate trials, review eligibility criteria
2. Week 1 to 2: Contact site coordinator at closest site, confirm slots are open
3. Week 2 to 3: Complete phone pre-screen, confirm washout requirements
4. Week 3 to 5: Attend in-person screening visit, sign ICD, complete baseline bloodwork and symptom diary
5. Week 5 to 7: Complete 2-week run-in diary, return for randomization visit
6. Week 7 onward: Receive study drug or placebo, begin protocol visits

If the first site has closed enrollment, repeat the process with your second-choice site. Trials at academic medical centers often have longer queues than community research sites affiliated with the same sponsor.